Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
People with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and hypertension than the general population. This results in an increased incidence of cardiovascuLar disease (CVD) and reduced Life expectancy, over and above that imposed by their mentaL illness through suicide. Several Levels of evidence from data Linkage analyses to clinical trials demonstrate that treatment-related metabolic disturbances are commonplace in this patient group, and that the use of certain second-generation antipsychotics may compound the risk of developing the metabolic syndrome and CVD. In addition, smoking, poor diet, reduced physical activity and alcohol or drug abuse are prevalent in people with schizophrenia and contribute to the overall CVD risk. Management and minimization of metaboLic risk factors are pertinent when providing optimal care to patients with schizophrenia. This review recommends a framework for the assessment, monitoring and management of patients with schizophrenia in the UK clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 1×
“Importantly, the total risk is significantly higher than the sum of individual risk factors (Wilson et al., 1998), suggesting a multiplicative inter-relationship and scope for considerable benefits from successful intervention.”
BackgroundGlucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Evidence suggests that the prevalence of DM in people with schizophrenia as well as in people with bipolar disorder and schizoaffective disorder is 2-3 fold higher compared with the general population (103,209-216).”
BackgroundDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
“…et al. 2004 ; Melkersson et al. 2004 ; De Nayer et al. 2005 ; Poulin et al. 2005 ; Amati et al. 2006 ; Lefebvre et al. 2006 ; Usher et al. 2006 ; Barnett et al. 2007; Cahn et al. 2008 ; Elkis et al. 2008 ; Murasaki et al. 2008 ; Saiz et al. 2008 ; De Hert et al. 2009 ; Saravane et al. 2009 ;…”
Background
Metadata
- Authors
- Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., TayLor, D., Vora, J., & Jones, P. B.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2007-06
- Volume
- 21
- Issue
- 4
- Pages
- 357-373
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2161605094
- Cited by
- 165
- References
- 80
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. https://app.cochat.ai/papers/10.1177/0269881107075509
- The paper
- Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., TayLor, D., Vora, J., & Jones, P. B. (2007). Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology. https://doi.org/10.1177/0269881107075509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.